Polycyclic GABA Derivative Design for α2δ Channel Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic neuropathic pain, such as antidepressants, anticonvulsants, and analgesics, have low efficacy and numerous side effects, with no specific drugs available to effectively prevent or relieve neuropathy, and existing voltage-gated calcium ion channel α2δ subunit ligands like gabapentin and pregabalin have limitations in dosage and absorption.
Innovation Solution
Development of a γ-aminobutyric acid derivative with a polycyclic structure that acts as a potent ligand for the human voltage-gated calcium ion channel α2δ subunit, offering a new therapeutic approach for chronic neuropathic pain, epilepsy, and anxiety, with improved efficacy and reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of gabapentin are used to achieve good therapeutic effect, then pain relief efficacy is improved, but absorption saturation occurs and action is delayed
Solution Approach 1:
The patent modifies the chemical structure of gabapentin by introducing a cyclic amino acid moiety to create new derivatives (compounds of formula I) with altered pharmacokinetic properties. This structural parameter change enables improved oral bioavailability and faster onset of action while maintaining therapeutic efficacy at lower doses, resolving the contradiction between therapeutic effect and absorption rate.
2Reliability
If tricyclic antidepressant drugs are used to treat chronic neuropathic pain, then pain relief is achieved, but numerous side effects occur including anticholinergic effects, CNS toxicity, and cardiovascular toxicity
Solution Approach 1:
The patent extracts and optimizes the beneficial analgesic property from antidepressant mechanisms by designing compounds that specifically target voltage-gated calcium channels. The γ-aminobutyric acid derivative structure selectively binds to α2δ subunits, separating the desired pain relief effect from the harmful anticholinergic and cardiovascular side effects associated with tricyclic antidepressants.
Solution Approach 2:
The patent changes the molecular target parameter from non-specific antidepressant receptors to specific voltage-gated calcium channel α2δ subunits. This target specificity parameter change enables effective pain relief while minimizing off-target side effects, resolving the contradiction between efficacy and safety.
3Reliability
If sodium ion channel blockers are used to treat chronic neuropathic pain, then pain relief is achieved, but many adverse reactions occur such as rash, nausea, vomiting, dizziness, fatigue, and blurred vision
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular characteristics (γ-aminobutyric acid derivative with cyclic amino acid) that confer selective affinity for voltage-gated calcium channels. This localized molecular property ensures the drug acts specifically on the intended target, producing pain relief without the broad-spectrum adverse reactions seen with sodium ion channel blockers.
4Reliability
If opioids are used to treat neuropathic pain, then some pain relief is achieved, but many side effects and addiction occur
Solution Approach 1:
The patent introduces a new mechanism of action as an intermediary between existing treatments and effective pain relief. The γ-aminobutyric acid derivative acts as a mediator by modulating voltage-gated calcium channel activity, providing analgesic effects through a novel pathway that avoids the side effects and addiction risks associated with opioid receptors while achieving comparable or superior pain relief.
Data Source
Figure 1~2
Figure 3A~5
Figure 6~7
AI summary
The invention relates to the field of pharmaceuticals. Specifically, the present application relates to a voltage-gated calcium ion channel α2δ subunit ligand comprising a polycyclic γ-aminobutyric acid structure represented by general formula I, a method for preparing same, and use thereof in the treatment of chronic neuropathic pain, epilepsy, and anxiety.